Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD) (NCT07751640)
A Single-Arm, Open-Label, Within-Subject Pilot Study (Phase I/IIa) Evaluating the Safety, Tolerability, and Exploratory Epigenetic Outcomes of a Single Same-Day Administration of Autologous Bone Marrow Aspirate (Intravenous) and Autologous Bone Marrow Aspirate Concentrate (Intranasal) in Adults With Parkinson's Disease or Parkinson-Plus Syndromes
🩺 Plain-English Summary (8th-Grade Level)
This pilot study evaluated the safety, tolerability, and exploratory epigenetic outcomes of a single same-day autologous bone marrow procedure in adults with Parkinson's disease (PD) or Parkinson-plus syndromes (PPS). Ten participants underwent posterior superior iliac spine bone marrow aspiration under local anesthesia. The unprocessed aspirate (BMA) was filtered and administered intravenously via normal saline infusion on the same day. A portion of the aspirate was centrifuged to produce a bone marrow aspirate concentrate (BMAC), which was atomized intranasally using a mucosal atomization device. Cells were not expanded in culture or genetically modified. The procedure was performed under the Same Surgical Procedure exception (21 CFR 1271.15(b)); an investigational new drug application (IND 31770) was submitted to the FDA Center for Biologics Evaluation and Research (CBER). The primary outcome was safety and tolerability, assessed by treatment-emergent adverse events (TEAEs) graded per CTCAE v5.0 criteria through 12 months post-treatment. Exploratory outcomes included DNA methylation biological age (GrimAge-based composite and organ/system Systems Age clocks) measured from peripheral blood at baseline and approximately 6 months, and characterization of the delivered cell product by automated hematology and multiparameter flow cytometry.
Who can join: Review the eligibility criteria below.
Location: Boulder Biologics Research Center — Boulder, Colorado
Age range: 40 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Boulder Biologics Research Center — Boulder, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in PARKINSON DISEASE (Disorder)
- Prescriptive Infusion Algorithm (PIA) — Cleveland, Ohio
- SwallowFIT Study in Parkinson's Disease — San Antonio, Texas
- Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation — Richardson, Texas
- Multicontext Approach for Cognitive Function in Parkinson Disease — St Louis, Missouri
- Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms — Cleveland, Ohio
Explore by condition: All PARKINSON DISEASE (Disorder) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.